Millier Aurelie, Cohen Joshua, Toumi Mondher
Health Economics and Outcomes Research Department, Creativ-Ceutical, Paris, France.
Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, United States of America.
PLoS One. 2013 Dec 19;8(12):e84088. doi: 10.1371/journal.pone.0084088. eCollection 2013.
Triptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-to-OTC switch in six EU countries (France, UK, Spain, Italy, Germany and Poland).
A decision model was used to model the budgetary impact of a triptan Rx-to-OTC switch from the third-party payer (TPP) and the societal perspectives, using a one-year timeframe.
From the TPP perspective, it is estimated that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million annually, and that the savings would reach €75 million (13% of the overall direct economic burden of migraine). From the societal perspective, €86 million annually would be added.
Given evidence of effectiveness and safety, and given the potential savings, a triptan Rx-to-OTC switch is a reasonable public policy decision.
曲坦类药物已安全有效地用于偏头痛治疗超过十五年，因此人们不禁会想，将一种特定曲坦类药物转为非处方药会产生怎样的经济影响。本研究的目的是考察在六个欧盟国家（法国、英国、西班牙、意大利、德国和波兰）将一种曲坦类药物从处方药转为非处方药的支付方政策所产生的经济影响。
采用决策模型，从第三方支付方（TPP）和社会角度，以一年为时间框架，模拟曲坦类药物从处方药转为非处方药的预算影响。
从TPP角度估计，目前欧盟6个成员国每年用于偏头痛发作治疗的总体直接支出为5.82亿欧元，节省金额将达7500万欧元（占偏头痛总体直接经济负担的13%）。从社会角度看，每年将增加8600万欧元。
鉴于有效性和安全性证据以及潜在的节省，将曲坦类药物从处方药转为非处方药是一项合理的公共政策决策。
